Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Ovarian Neoplasms

  Free Subscription


Articles published in Cancer Res

Retrieve available abstracts of 110 articles:
HTML format



Single Articles


    June 2021
  1. PATEL M, Wang Y, Bartom ET, Dhir R, et al
    The ratio of toxic-to-nontoxic microRNAs predicts platinum sensitivity in ovarian cancer.
    Cancer Res. 2021 Jun 15. pii: 0008-5472.CAN-21-0953.
    PubMed     Abstract available


    April 2021
  2. SCHOUTROP E, El-Serafi I, Poiret T, Zhao Y, et al
    Mesothelin-specific CAR T cells target ovarian cancer.
    Cancer Res. 2021 Apr 1. pii: 0008-5472.CAN-20-2701.
    PubMed     Abstract available


    February 2021
  3. BELUR NAGARAJ A, Knarr M, Sekhar S, Connor RS, et al
    The miR-181a-SFRP4 axis regulates Wnt activation to drive stemness and platinum resistance in ovarian cancer.
    Cancer Res. 2021 Feb 11. pii: 0008-5472.CAN-20-2041.
    PubMed     Abstract available


    December 2020
  4. KARLSSON T, Johansson T, Hoglund J, Ek WE, et al
    Time-dependent effects of oral contraceptive use on breast, ovarian and endometrial cancers.
    Cancer Res. 2020 Dec 17. pii: 0008-5472.CAN-20-2476.
    PubMed     Abstract available


    November 2020
  5. DRERUP JM, Deng Y, Pandeswara SL, Padron AS, et al
    CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.
    Cancer Res. 2020;80:5063-5075.
    PubMed     Abstract available


  6. WANG Y, Zhao G, Condello S, Huang H, et al
    Frizzled-7 Identifies Platinum Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis.
    Cancer Res. 2020 Nov 10. pii: 0008-5472.CAN-20-1488.
    PubMed     Abstract available


  7. WAN C, Keany MP, Dong H, Al-Alem LF, et al
    Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high grade serous ovarian cancer.
    Cancer Res. 2020 Nov 6. pii: 0008-5472.CAN-20-1674.
    PubMed     Abstract available


    October 2020
  8. PARASHAR D, Nair B, Geethadevi A, George J, et al
    Peritoneal Spread of Ovarian Cancer harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling.
    Cancer Res. 2020 Oct 21. pii: 0008-5472.CAN-19-3717.
    PubMed     Abstract available


  9. SHEN YA, Hong J, Asaka R, Asaka S, et al
    Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
    Cancer Res. 2020;80:4514-4526.
    PubMed     Abstract available


    September 2020
  10. TAMURA N, Shaikh N, Muliaditan D, Soliman TN, et al
    Specific mechanisms of chromosomal instability indicate therapeutic sensitivities in high-grade serous ovarian carcinoma.
    Cancer Res. 2020 Sep 30. pii: 0008-5472.CAN-19-0852.
    PubMed     Abstract available


  11. HUANG TT, Brill E, Nair JR, Zhang X, et al
    Targeting the PI3K/mTOR pathway augments CHK1 inhibitor-induced replication stress and antitumor activity in high-grade serous ovarian cance.
    Cancer Res. 2020 Sep 30. pii: 0008-5472.CAN-20-1439.
    PubMed     Abstract available


  12. AZAR WJ, Christie EL, Mitchell C, Liu DS, et al
    Non-canonical IL-6 signaling-mediated activation of YAP regulates cell migration and invasion in ovarian clear cell cancer.
    Cancer Res. 2020 Sep 11. pii: 0008-5472.CAN-19-3044.
    PubMed     Abstract available


  13. CARLES A, Trigo-Gonzalez G, Cao Q, Cheng SG, et al
    The Pathognomonic FOXL2 C134W Mutation Alters DNA-Binding Specificity.
    Cancer Res. 2020;80:3480-3491.
    PubMed     Abstract available


  14. WEIS-BANKE SE, Lerdrup M, Kleine-Kohlbrecher D, Mohammad F, et al
    Mutant FOXL2(C134W) Hijacks SMAD4 and SMAD2/3 to Drive Adult Granulosa Cell Tumors.
    Cancer Res. 2020;80:3466-3479.
    PubMed     Abstract available


  15. TUBEUF H, Caputo SM, Sullivan T, Rondeaux J, et al
    Calibration of Pathogenicity Due to Variant-Induced Leaky Splicing Defects by Using BRCA2 Exon 3 as a Model System.
    Cancer Res. 2020;80:3593-3605.
    PubMed     Abstract available


    August 2020
  16. ZONG X, Wang W, Ozes A, Fang F, et al
    EZH2-mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.
    Cancer Res. 2020 Aug 19. pii: 0008-5472.CAN-20-0458.
    PubMed     Abstract available


  17. PALMER AC, Plana D, Gao H, Korn JM, et al
    A proof of concept for biomarker-guided targeted therapy against ovarian cancer based on patient-derived tumor xenografts.
    Cancer Res. 2020 Aug 3. pii: 0008-5472.CAN-19-3850.
    PubMed     Abstract available


  18. GEISTLINGER L, Oh S, Ramos M, Schiffer L, et al
    Multi-omic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma.
    Cancer Res. 2020 Aug 3. pii: 0008-5472.CAN-20-0521.
    PubMed     Abstract available


    July 2020
  19. ASARE-WEREHENE M, Communal L, Carmona E, Han Y, et al
    Plasma gelsolin inhibits CD8+ T cell function and regulates glutathione production to confer chemoresistance in ovarian cancer.
    Cancer Res. 2020 Jul 8. pii: 0008-5472.CAN-20-0788.
    PubMed     Abstract available


    June 2020
  20. HUANG H, Wang Y, Kandpal M, Zhao G, et al
    FTO-Dependent N6-Methyladenosine Modifications Inhibit Ovarian Cancer Stem Cell Self-Renewal by Blocking cAMP Signaling.
    Cancer Res. 2020 Jun 30. pii: 0008-5472.CAN-19-4044.
    PubMed     Abstract available


    May 2020
  21. MATEI D, Nephew KP
    Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes.
    Cancer Res. 2020 May 7. pii: 0008-5472.CAN-19-3837.
    PubMed     Abstract available


    April 2020
  22. MEULEMANS L, Mesman RLS, Caputo SM, Krieger S, et al
    Skipping Nonsense to Maintain Function: The Paradigm of BRCA2 Exon 12.
    Cancer Res. 2020;80:1374-1386.
    PubMed     Abstract available


    February 2020
  23. MCCOOL KW, Freeman ZT, Zhai Y, Wu R, et al
    Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
    Cancer Res. 2020;80:877-889.
    PubMed     Abstract available


  24. MUKHERJEE A, Chiang CY, Daifotis HA, Nieman KM, et al
    Adipocyte-induced FABP4 expression in ovarian cancer cells promotes metastasis and mediates carboplatin resistance.
    Cancer Res. 2020 Feb 13. pii: 0008-5472.CAN-19-1999.
    PubMed     Abstract available


    January 2020
  25. ZELEZNIK OA, Eliassen AH, Kraft P, Poole EM, et al
    A prospective analysis of circulating plasma metabolites associated with ovarian cancer risk.
    Cancer Res. 2020 Jan 22. pii: 0008-5472.CAN-19-2567.
    PubMed     Abstract available


  26. TRABERT B, Tworoger SS, O'Brien KM, Townsend MK, et al
    The risk of ovarian cancer increases with an increase in the lifetime number of ovulatory cycles: an analysis from the Ovarian Cancer Cohort Consortium (OC3).
    Cancer Res. 2020 Jan 13. pii: 0008-5472.CAN-19-2850.
    PubMed     Abstract available


  27. ASEM M, Young AM, Oyama C, Claure De La Zerda AG, et al
    Host Wnt5a Potentiates Microenvironmental Regulation of Ovarian Cancer Metastasis.
    Cancer Res. 2020 Jan 13. pii: 0008-5472.CAN-19-1601.
    PubMed     Abstract available


    December 2019
  28. NACARELLI T, Fukumoto T, Zundell JA, Fatkhutdinov N, et al
    NAMPT inhibition suppresses cancer stem-like cells associated with therapy-induced senescence in ovarian cancer.
    Cancer Res. 2019 Dec 19. pii: 0008-5472.CAN-19-2830.
    PubMed     Abstract available


  29. MOYER CL, Ivanovich J, Gillespie JL, Doberstein R, et al
    Rare BRIP1 missense alleles confer risk for ovarian and breast cancer.
    Cancer Res. 2019 Dec 10. pii: 0008-5472.CAN-19-1991.
    PubMed     Abstract available


    November 2019
  30. LI C, Course MM, McNeish IA, Drescher CW, et al
    Prophylactic in vivo hematopoietic stem cell gene therapy with an immune checkpoint inhibitor reverses tumor growth in syngeneic mouse tumor models.
    Cancer Res. 2019 Nov 14. pii: 0008-5472.CAN-19-1044.
    PubMed     Abstract available


    October 2019
  31. KANAKKANTHARA A, Kurmi K, Ekstrom TL, Hou X, et al
    BRCA1 Deficiency Upregulates NNMT Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.
    Cancer Res. 2019 Oct 16. pii: 0008-5472.CAN-19-1405.
    PubMed     Abstract available


  32. CARBONE M, Melino G
    Stearoyl CoA Desaturase Regulates Ferroptosis in Ovarian Cancer Offering New Therapeutic Perspectives.
    Cancer Res. 2019;79:5149-5150.
    PubMed     Abstract available


    September 2019
  33. CHUI MH, Doodnauth SA, Erdmann N, Tiedemann RE, et al
    Chromosomal instability and mTORC1 activation through PTEN loss contribute to proteotoxic stress in ovarian carcinoma.
    Cancer Res. 2019 Sep 17. pii: 0008-5472.CAN-18-3029.
    PubMed     Abstract available


  34. ROBERTS AL, Huang T, Koenen KC, Kim Y, et al
    Posttraumatic stress disorder (PTSD) is associated with increased risk of ovarian cancer: a prospective and retrospective longitudinal cohort study.
    Cancer Res. 2019 Sep 5. pii: 0008-5472.CAN-19-1222.
    PubMed     Abstract available


    August 2019
  35. PERES LC, Mallen AR, Townsend MK, Poole EM, et al
    High levels of C-reactive protein are associated with an increased risk of ovarian cancer: Results from the Ovarian Cancer Cohort Consortium.
    Cancer Res. 2019 Aug 28. pii: 0008-5472.CAN-19-1554.
    PubMed     Abstract available


    July 2019
  36. SHANG S, Yang J, Jazaeri AA, Duval AJ, et al
    Chemotherapy-induced distal enhancers drive transcriptional program to maintain the chemoresistant state in ovarian cancer.
    Cancer Res. 2019 Jul 29. pii: 0008-5472.CAN-19-0215.
    PubMed     Abstract available


  37. FUKUMOTO T, Fatkhutdinov N, Zundell JA, Tcyganov EN, et al
    HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer.
    Cancer Res. 2019 Jul 16. pii: 0008-5472.CAN-19-1302.
    PubMed     Abstract available


  38. TESFAY L, Paul BT, Konstorum A, Deng Z, et al
    Steroyl-CoA Desaturase 1 (SCD1) protects ovarian cancer cells from ferroptotic cell death.
    Cancer Res. 2019 Jul 3. pii: 0008-5472.CAN-19-0369.
    PubMed     Abstract available


    June 2019
  39. FUKUMOTO T, Zhu H, Nacarelli T, Karakashev S, et al
    N(6)-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance.
    Cancer Res. 2019;79:2812-2820.
    PubMed     Abstract available


    May 2019
  40. MUYS BR, Sousa JF, Placa JR, Araujo LF, et al
    miR-450a acts as a tumor suppressor in ovarian cancer by regulating energy metabolism.
    Cancer Res. 2019 May 17. pii: 0008-5472.CAN-19-0490.
    PubMed     Abstract available


  41. DORAYAPPAN KDP, Gardner ML, Hisey CL, Zingarelli RA, et al
    A microfluidic chip enables isolation of exosomes and establishment of their protein profiles and associated signaling pathways in ovarian cancer.
    Cancer Res. 2019 May 16. pii: 0008-5472.CAN-18-3538.
    PubMed     Abstract available


  42. TRAVERS M, Brown SM, Dunworth M, Holbert CE, et al
    DFMO and 5-azacytidine increase M1 macrophages in the tumor microenvironment of murine ovarian cancer.
    Cancer Res. 2019 May 14. pii: 0008-5472.CAN-18-4018.
    PubMed     Abstract available


  43. MUKHERJEE A, Huynh V, Gaines K, Reh WA, et al
    Targeting the High Mobility Group Box 3 protein sensitizes chemoresistant ovarian cancer cells to cisplatin.
    Cancer Res. 2019 May 6. pii: 0008-5472.CAN-19-0542.
    PubMed     Abstract available


    April 2019
  44. RAMAMOORTHY P, Thomas SM, Kaushik G, Subramaniam D, et al
    Metastatic Tumor-in-a-Dish, a Novel Multicellular Organoid to Study Lung Colonization and Predict Therapeutic Response.
    Cancer Res. 2019;79:1681-1695.
    PubMed     Abstract available


    March 2019
  45. PRICE C, Gill S, Ho ZV, Davidson SM, et al
    Genome-wide interrogation of human cancers identifies EGLN1 dependency in clear cell ovarian cancers.
    Cancer Res. 2019 Mar 21. pii: 0008-5472.CAN-18-2674.
    PubMed     Abstract available


  46. SRIVASTAVA AK, Banerjee A, Cui T, Han C, et al
    Inhibition of miR-328-3p impairs cancer stem cell function and prevents metastasis in ovarian cancer.
    Cancer Res. 2019 Mar 20. pii: 0008-5472.CAN-18-3668.
    PubMed     Abstract available


  47. NATARAJAN S, Foreman KM, Soriano MI, Rossen NS, et al
    Collagen remodeling in the hypoxic tumor-mesothelial niche promotes ovarian cancer metastasis.
    Cancer Res. 2019 Mar 12. pii: 0008-5472.CAN-18-2616.
    PubMed     Abstract available


    February 2019
  48. MCCORMICK PN, Greenwood HE, Glaser M, Maddocks ODK, et al
    Assessment of Tumor Redox Status through (S)-4-(3-[(18)F]fluoropropyl)-L-Glutamic Acid PET Imaging of System xc (-) Activity.
    Cancer Res. 2019;79:853-863.
    PubMed     Abstract available


  49. CHOI J, Brown KM
    A Dynamic Cis-Regulation Pattern Underlying Epithelial Ovarian Cancer Susceptibility.
    Cancer Res. 2019;79:439-440.
    PubMed     Abstract available


    January 2019
  50. DYER A, Schoeps B, Frost S, Jakeman P, et al
    Antagonism of Glycolysis and Reductive Carboxylation of Glutamine Potentiates Activity of Oncolytic Adenoviruses in Cancer Cells.
    Cancer Res. 2019;79:331-345.
    PubMed     Abstract available


  51. SHEN J, Zhao W, Ju Z, Wang L, et al
    PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
    Cancer Res. 2019;79:311-319.
    PubMed     Abstract available


    December 2018
  52. HOODA J, Novak M, Salomon MP, Matsuba C, et al
    Early loss of Histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer.
    Cancer Res. 2018 Dec 18. pii: 0008-5472.CAN-18-2297.
    PubMed     Abstract available


  53. YANG Y, Wu L, Shu X, Lu Y, et al
    Genetic data from nearly 63,000 women of European descent predicts DNA methylation biomarkers and epithelial ovarian cancer risk.
    Cancer Res. 2018 Dec 17. pii: 0008-5472.CAN-18-2726.
    PubMed     Abstract available


    November 2018
  54. BUCKLEY MA, Woods NT, Tyrer JP, Mendoza-Fandino G, et al
    Functional analysis and fine mapping of the 9p22.2 ovarian cancer susceptibility locus.
    Cancer Res. 2018 Nov 28. pii: 0008-5472.CAN-17-3864.
    PubMed     Abstract available


    October 2018

  55. Correction: RSF1 Is a Positive Regulator of NFkappaB-induced Gene Expression Required for Ovarian Cancer Chemoresistance.
    Cancer Res. 2018;78:6024.
    PubMed    


    September 2018
  56. LIU M, Thomas SL, DeWitt AK, Zhou W, et al
    Dual inhibition of DNA and histone methyltransferases increases viral mimicry in ovarian cancer cells.
    Cancer Res. 2018 Sep 5. pii: 0008-5472.CAN-17-3953.
    PubMed     Abstract available


    August 2018
  57. BYEON Y, Lee JW, Choi WS, Won JE, et al
    CD44-targeted PLGA nanoparticles incorporating paclitaxel and FAK siRNA overcome chemoresistance in epithelial ovarian cancer.
    Cancer Res. 2018 Aug 16. pii: 0008-5472.CAN-17-3871.
    PubMed     Abstract available



  58. Correction: Significance of MAD2 Expression to Mitotic Checkpoint Control in Ovarian Cancer Cells.
    Cancer Res. 2018;78:4800.
    PubMed    


  59. BELANGER F, Fortier E, Dube M, Lemay JF, et al
    Replication Protein A Availability During DNA Replication Stress Is a Major Determinant of Cisplatin Resistance in Ovarian Cancer Cells.
    Cancer Res. 2018 Aug 2. pii: 0008-5472.CAN-18-0618.
    PubMed     Abstract available


    July 2018
  60. LU Y, Beeghly-Fadiel A, Wu L, Guo X, et al
    A transcriptome-wide association study among 97,898 women to identify candidate susceptibility genes for epithelial ovarian cancer risk.
    Cancer Res. 2018 Jul 27. pii: 0008-5472.CAN-18-0951.
    PubMed     Abstract available



  61. Correction: Metronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian Cancer.
    Cancer Res. 2018;78:4099.
    PubMed    



  62. Correction: FIH Is an Oxygen Sensor in Ovarian Cancer for G9a/GLP-Driven Epigenetic Regulation of Metastasis-Related Genes.
    Cancer Res. 2018;78:3742.
    PubMed    


    June 2018

  63. Correction: Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells.
    Cancer Res. 2018;78:3402.
    PubMed    


  64. HIRST J, Pathak HB, Hyter S, Pessetto ZY, et al
    Licofelone enhances the efficacy of paclitaxel in ovarian cancer by reversing drug resistance and tumor stem-like properties.
    Cancer Res. 2018 Jun 11. pii: 0008-5472.CAN-17-3993.
    PubMed     Abstract available


    May 2018
  65. HAUTANIEMI S, Kozlowska E, Farkkila A, Vallius T, et al
    Mathematical modeling predicts response to chemotherapy and drug combinations in ovarian cancer.
    Cancer Res. 2018 May 16. pii: 0008-5472.CAN-17-3746.
    PubMed     Abstract available


  66. SALEM M, O'Brien JA, Bernaudo S, Shawer H, et al
    miRNA-590-3p promotes ovarian cancer growth and metastasis via a novel FOXA2-versican pathway.
    Cancer Res. 2018 May 10. pii: 0008-5472.CAN-17-3014.
    PubMed     Abstract available


  67. CARROLL MJ, Fogg KC, Patel HA, Krause HB, et al
    Alternatively activated macrophages upregulate mesothelial expression of P-selectin to enhance adhesion of ovarian cancer cells.
    Cancer Res. 2018 May 8. pii: 0008-5472.CAN-17-3341.
    PubMed     Abstract available


  68. LUO XL, Deng C, Su XD, Wang F, et al
    Loss of MED12 induces tumor dormancy in human epithelial ovarian cancer via downregulation of EGFR.
    Cancer Res. 2018 May 7. pii: 0008-5472.CAN-18-0134.
    PubMed     Abstract available


    April 2018
  69. SHARMA SK, Chow A, Monette S, Vivier D, et al
    Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.
    Cancer Res. 2018;78:1820-1832.
    PubMed     Abstract available


  70. SAINI U, Suarez AA, Naidu S, Wallbillich JJ, et al
    STAT3/PIAS3 Levels Serve as "Early Signature" Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube.
    Cancer Res. 2018;78:1739-1750.
    PubMed     Abstract available


    March 2018
  71. CONDELLO S, Sima LE, Ivan C, Cardenas H, et al
    Tissue transglutaminase regulates interactions between ovarian cancer stem cells and the tumor niche.
    Cancer Res. 2018 Mar 6. pii: 0008-5472.CAN-17-2319.
    PubMed     Abstract available


    January 2018
  72. HA JH, Radhakrishnan R, Jayaraman M, Yan M, et al
    Lysophosphatidic Acid Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response.
    Cancer Res. 2018 Jan 31. pii: 0008-5472.CAN-17-1624.
    PubMed     Abstract available


  73. ZHANG Y, Li L, Wang L, Li J, et al
    Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer.
    Cancer Res. 2018 Jan 26. pii: 0008-5472.CAN-17-2460.
    PubMed     Abstract available


  74. CURRY E, Zeller C, Masrour N, Patten D, et al
    Genes predisposed to DNA hypermethylation during acquired resistance to chemotherapy are identified in ovarian tumors by bivalent chromatin domains at initial diagnosis.
    Cancer Res. 2018 Jan 16. pii: 0008-5472.CAN-17-1650.
    PubMed     Abstract available


  75. LU Y, Hu Z, Mangala LS, Stine ZE, et al
    MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels.
    Cancer Res. 2018;78:64-74.
    PubMed     Abstract available


    December 2017
  76. KANG J, Shin SH, Yoon H, Huh J, et al
    FIH is an oxygen sensor in ovarian cancer for G9a/GLP-driven epigenetic regulation of metastasis-related genes.
    Cancer Res. 2017 Dec 19. pii: 0008-5472.CAN-17-2506.
    PubMed     Abstract available


  77. FANG F, Cardenas H, Huang H, Jiang G, et al
    Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Re-sensitization to Platinum Drugs.
    Cancer Res. 2017 Dec 11. pii: 0008-5472.CAN-17-1492.
    PubMed     Abstract available


    November 2017
  78. HIRAMATSU K, Serada S, Enomoto T, Takahashi Y, et al
    LSR antibody therapy inhibits ovarian epithelial tumor growth by inhibiting lipid uptake.
    Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0910.
    PubMed     Abstract available


    October 2017
  79. HOUSE CD, Jordan E, Hernandez L, Ozaki M, et al
    NF-kB promotes ovarian tumorigenesis via classical pathways supporting proliferative cancer cells and alternative pathways supporting ALDH+ cancer stem-like cells.
    Cancer Res. 2017 Oct 26. pii: canres.0366.2017.
    PubMed     Abstract available


  80. CICHOCKI F, Valamehr B, Bjordahl R, Zhang B, et al
    GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity.
    Cancer Res. 2017;77:5664-5675.
    PubMed     Abstract available


  81. LAMICHHANE P, Karyampudi L, Shreeder B, Krempski J, et al
    IL-10 release upon PD-1 blockade sustains immunosuppression in ovarian cancer.
    Cancer Res. 2017 Oct 9. pii: canres.0740.2017.
    PubMed     Abstract available


  82. GALL VA, Philips AV, Qiao N, Clise-Dwyer K, et al
    Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.
    Cancer Res. 2017;77:5374-5383.
    PubMed     Abstract available


    September 2017
  83. YIN X, Jing Y, Cai MC, Ma P, et al
    Clonality, heterogeneity and evolution of synchronous bilateral ovarian cancer.
    Cancer Res. 2017 Sep 28. pii: canres.1461.2017.
    PubMed     Abstract available


  84. FALCETTA F, Bizzaro F, D'Agostini E, Bani MR, et al
    Modeling cytostatic and cytotoxic responses to new treatment regimens for ovarian cancer.
    Cancer Res. 2017 Sep 26. pii: canres.1099.2017.
    PubMed     Abstract available


    July 2017
  85. ZHU W, Jarman KE, Lokman NA, Neubauer HA, et al
    CIB2 negatively regulates oncogenic signaling in ovarian cancer via sphingosine kinase 1.
    Cancer Res. 2017 Jul 20. pii: canres.0025.2017.
    PubMed     Abstract available


  86. PIACENTE F, Caffa I, Ravera S, Sociali G, et al
    Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
    Cancer Res. 2017;77:3857-3869.
    PubMed     Abstract available


  87. YANG D, Sun B, Zhang X, Cheng D, et al
    Huwe1 sustains normal ovarian epithelial cell transformation and tumor growth through the histone H1.3-H19 cascade.
    Cancer Res. 2017 Jul 7. pii: canres.2597.2016.
    PubMed     Abstract available


    June 2017
  88. MARCHAN R, Buttner B, Lambert J, Edlund K, et al
    Glycerol-3-phosphate acyltransferase 1 promotes tumor cell migration and poor survival in ovarian carcinoma.
    Cancer Res. 2017 Jun 26. pii: canres.2065.2016.
    PubMed     Abstract available


  89. ETEMADMOGHADAM D, Azar WJ, Lei Y, Moujaber T, et al
    EIF1AX and NRAS mutations co-occur and cooperate in low-grade serous ovarian carcinomas.
    Cancer Res. 2017 Jun 23. pii: canres.2224.2016.
    PubMed     Abstract available


  90. RIVERA B, Di Iorio M, Frankum J, Nadaf J, et al
    Functionally null RAD51D missense mutation associates strongly with ovarian carcinoma.
    Cancer Res. 2017 Jun 23. pii: canres.0190.2017.
    PubMed     Abstract available


    May 2017

  91. Correction: Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.
    Cancer Res. 2017;77:2770.
    PubMed    


    April 2017
  92. SANS M, Gharpure KM, Tibshirani R, Zhang J, et al
    Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging.
    Cancer Res. 2017 Apr 17. pii: canres.3044.2016.
    PubMed     Abstract available



  93. Correction: EGFL6 Regulates the Asymmetric Division, Maintenance, and Metastasis of ALDH+ Ovarian Cancer Cells.
    Cancer Res. 2017;77:2175.
    PubMed    


  94. WANG L, Shi C, Wright FA, Guo D, et al
    Multifunctional Telodendrimer Nanocarriers Restore Synergy of Bortezomib and Doxorubicin in Ovarian Cancer Treatment.
    Cancer Res. 2017 Apr 10. pii: canres.3119.2016.
    PubMed     Abstract available


  95. OSE J, Poole EM, Schock H, Lehtinen M, et al
    Androgens are differentially associated with ovarian cancer subtypes in the Ovarian Cancer Cohort Consortium.
    Cancer Res. 2017 Apr 5. pii: canres.3322.2016.
    PubMed     Abstract available


    March 2017
  96. JOSEPHS DH, Bax HJ, Dodev T, Georgouli M, et al
    Anti-Folate Receptor-alpha IgE but not IgG Recruits Macrophages to Attack Tumors via TNFalpha/MCP-1 Signaling.
    Cancer Res. 2017;77:1127-1141.
    PubMed     Abstract available


    February 2017
  97. CHEN MW, Yang ST, Chien MH, Hua KT, et al
    The STAT3-miRNA-92-Wnt signaling pathway regulates spheroid formation and malignant progression in ovarian cancer.
    Cancer Res. 2017 Feb 16. pii: canres.1115.2016.
    PubMed     Abstract available


  98. SUNDARAM KM, Zhang Y, Mitra AK, Kouadio JK, et al
    Prolactin receptor-mediated internalization of imaging agents detects epithelial ovarian cancer with enhanced sensitivity and specificity.
    Cancer Res. 2017 Feb 15. pii: canres.1454.2016.
    PubMed     Abstract available


  99. JUNG M, Russell AJ, Liu B, George J, et al
    A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers.
    Cancer Res. 2017;77:971-981.
    PubMed     Abstract available


    January 2017
  100. ZHAO L, Ji G, Le X, Wang C, et al
    Long non-coding RNA LINC00092 acts in cancer-associated fibroblasts to drive glycolysis and progression of ovarian cancer.
    Cancer Res. 2017 Jan 13. pii: canres.1615.2016.
    PubMed     Abstract available


    November 2016
  101. BAI S, Ingram P, Chen YC, Deng N, et al
    EGFL6 Regulates the Asymmetric Division, Maintenance, and Metastasis of ALDH+ Ovarian Cancer Cells.
    Cancer Res. 2016;76:6396-6409.
    PubMed     Abstract available


  102. YOKOYAMA Y, Zhu H, Lee JH, Kossenkov AV, et al
    BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer.
    Cancer Res. 2016;76:6320-6330.
    PubMed     Abstract available


  103. IORIO MV, Croce CM
    Commentary on microRNA Fingerprint in Human Epithelial Ovarian Cancer.
    Cancer Res. 2016;76:6143-6145.
    PubMed    


    October 2016
  104. KANLIKILICER P, Saber M, Bayraktar R, Mitra R, et al
    Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells.
    Cancer Res. 2016 Oct 14. pii: canres.0714.2016.
    PubMed     Abstract available


    September 2016
  105. CLARK CA, Gupta H, Sareddy GR, Pandeswara S, et al
    Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis and autophagy in ovarian cancer and melanoma.
    Cancer Res. 2016 Sep 26. pii: canres.0258.2016.
    PubMed     Abstract available


    August 2016
  106. WALTON J, Blagih J, Ennis D, Leung E, et al
    CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high grade serous carcinoma.
    Cancer Res. 2016 Aug 16. pii: canres.1272.2016.
    PubMed     Abstract available


    May 2016
  107. SCHULTZ MJ, Holdbrooks AT, Chakraborty A, Grizzle WE, et al
    The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype.
    Cancer Res. 2016 May 23. pii: canres.2834.2015.
    PubMed     Abstract available


  108. KIM SY, Ebbert K, Cordeiro MH, Romero MM, et al
    Constitutive activation of PI3K in oocytes induces ovarian granulosa cell tumors.
    Cancer Res. 2016 May 9. pii: canres.3358.2015.
    PubMed     Abstract available


    April 2016
  109. FEHRINGER G, Kraft P, Pharoah PD, Eeles RA, et al
    Cross-cancer genome-wide analysis of lung, ovary, breast, prostate and colorectal cancer reveals novel pleiotropic associations.
    Cancer Res. 2016 Apr 20. pii: canres.2980.2015.
    PubMed     Abstract available


    January 2016
  110. POPOVA T, Manie E, Boeva V, Battistella A, et al
    Ovarian cancers harboring inactivating mutations in CDK12 display a distinct genomic instability pattern characterized by large tandem duplications.
    Cancer Res. 2016 Jan 19. pii: canres.2128.2015.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: